Guillane Barre Syndrome (AIDP) Admission [663]

General	
Common Present on Admission Diagnosis	
[] Acidosis	Details
[] Acute Post-Hemorrhagic Anemia	Details
[] Acute Renal Failure	Details
[] Acute Respiratory Failure	Details
[] Acute Thromboembolism of Deep Veins of Lower Extremities	Details
[] Anemia	Details
[] Bacteremia	Details
Bipolar disorder, unspecified	Details
[] Cardiac Arrest	Details
[] Cardiac Dysrhythmia	Details
[] Cardiogenic Shock	Details
Decubitus Ulcer	Details
Dementia in Conditions Classified Elsewhere	Details
Disorder of Liver	Details
Electrolyte and Fluid Disorder	Details
Intestinal Infection due to Clostridium Difficile	Details
Methicillin Resistant Staphylococcus Aureus Infection	Details
Obstructive Chronic Bronchitis with Exacerbation	Details
Other Alteration of Consciousness	Details
Other and Unspecified Coagulation Defects	Details
Other Pulmonary Embolism and Infarction	Details
Phlebitis and Thrombophlebitis	Details
Protein-calorie Malnutrition	Details
Psychosis, unspecified psychosis type	Details
Schizophrenia Disorder	Details
Sepsis	Details
[] Septic Shock	Details
Septicemia	Details
[] Type II or Unspecified Type Diabetes Mellitus with Mention of Complication, Not Stated as Uncontrolled	Details
Urinary Tract Infection, Site Not Specified	Details
Admission or Observation (Single Response)	
	Diagnasia
() Admit to Inpatient	Diagnosis: Admitting Physician:
	Level of Care:
	Patient Condition:
	Bed request comments:
	Certification: I certify that based on my best clinical judgment
	and the patient's condition as documented in the HP and
	progress notes, I expect that the patient will need hospital
	services for two or more midnights.
() Outpatient observation services under general	Diagnosis:
supervision	Admitting Physician:
•	Patient Condition:
	Bed request comments:
() Outpatient in a bed - extended recovery	Diagnosis:
•	Admitting Physician:
	Bed request comments:
Admission or Observation (Single Response) Patient has active status order on file	
. a.c. nao aouro otatao oraon on mo	

() Admit to Inpatient	Diagnosis:
	Admitting Physician: Level of Care:
	Patient Condition:
	Bed request comments:
	Certification: I certify that based on my best clinical judgment
	and the patient's condition as documented in the HP and
	progress notes, I expect that the patient will need hospital
	services for two or more midnights.
() Outpatient observation services under general	Diagnosis:
supervision	Admitting Physician:
	Patient Condition:
() Outpatient in a lead, automoled resource.	Bed request comments:
() Outpatient in a bed - extended recovery	Diagnosis: Admitting Physician:
	Bed request comments:
	Dod roquest comments.
Admission (Single Response) Patient has active status order on file.	
() Admit to inpatient	Diagnosis:
	Admitting Physician:
	Level of Care:
	Patient Condition:
	Bed request comments:
	Certification: I certify that based on my best clinical judgment
	and the patient's condition as documented in the HP and progress notes, I expect that the patient will need hospital
	services for two or more midnights.
	Solvioss for two of more manighte.
Code Status	
[] Full code	Code Status decision reached by:
[] DNR	
[] DNR (Do Not Resuscitate)	Does patient have decision-making capacity?
[] Consult to Palliative Care Service	Priority:
	Reason for Consult? Order?
	Name of referring provider:
	Enter call back number:
[] Consult to Social Work	Reason for Consult:
Modified Code	Does patient have decision-making capacity?
	Modified Code restrictions:
[] Treatment Restrictions	Treatment Restriction decision reached by:
	Specify Treatment Restrictions:
loclation	
Isolation	
[] Airborne isolation status	Details
[] Contact isolation status	Details
[] Droplet isolation status	Details
[] Enteric isolation status	Details
Precautions	
[] Aspiration precautions	Details
[] Fall precautions	Increased observation level needed:
[] Latex precautions	Details
[] Seizure precautions	Increased observation level needed:
Nursing	

Nursing

Vital Signs

[] Vital Signs-Q4H	Routine, Every 4 hours For Until specified Until stable then every 8 hours
[] Vital Signs-Q6H	Routine, Every 6 hours
Activity	
[] Strict bed rest	Routine, Until discontinued, Starting S
Bed rest with bathroom privileges	Routine, Until discontinued, Starting S For Until specified Bathroom Privileges: with bathroom privileges
[] Out of bed	Routine, Until discontinued, Starting S Specify: Out of bed With assistance
Nursing	
[] Telemetry	"And" Linked Panel
[] Telemetry monitoring	Routine, Continuous Order: Place in Centralized Telemetry Monitor: EKG Monitoring Only (Telemetry Box) Reason for telemetry: Can be off of Telemetry for tests and baths? Yes
[] Telemetry Additional Setup Information	Routine, Continuous High Heart Rate (BPM): 120 Low Heart Rate(BPM): 50 High PVC's (per minute): 10 High SBP(mmHg): 175 Low SBP(mmHg): 100 High DBP(mmHg): 95 Low DBP(mmHg): 40 Low Mean BP: 60 High Mean BP: 120 Low SPO2(%): 94
[] Neurological Assessment	Routine, Every 4 hours Assessment to Perform: Then every 8 hours when patient is stable.
[] Neurological Assessment	Routine, Every 8 hours Assessment to Perform:
[] Commode at bedside	Routine, Once
[] Walker to bedside	Routine, Until discontinued, Starting S
[] Height and weight	Routine, Once On Admission
[] If patient is receiving plasma exchange therapy, ok to draw all ordered labs during plasma exchange process. Notify	Routine, Until discontinued, Starting S
[] Notify Physician	Routine, Until discontinued, Starting S, If Heart rate greater than 110 bpm, Shortness of breath, Forced Vital Capacity less than 15 milliliters per kilogram, and Negative Inspiratory Force less than -25 centimeters H2O.
[] Notify Resident	Routine, Until discontinued, Starting S, If Heart rate greater than 110 bpm, Shortness of breath, Forced Vital Capacity less than 15 milliliters per kilogram, and Negative Inspiratory Force less than -25 centimeters H2O.
Notify	
[] Notify Physician	Routine, Until discontinued, Starting S, If Heart rate greater than 110 bpm, Shortness of breath, Forced Vital Capacity less than 15 milliliters per kilogram, and Negative Inspiratory Force less than -25 centimeters H2O.
Diet	

[] NPO	Diet effective now, Starting S NPO:
[1 Diet Poguler	Pre-Operative fasting options:
[] Diet - Regular	Diet effective now, Starting S Diet(s): Regular
	Advance Diet as Tolerated?
	Liquid Consistency:
	Fluid Restriction:
	Foods to Avoid:
[] Diet - Heart healthy	Diet effective now, Starting S
[] Diet House Housely	Diet(s): Heart Healthy
	Advance Diet as Tolerated?
	Liquid Consistency:
	Fluid Restriction:
	Foods to Avoid:
[] Diet - Dysphagia Mechanically Altered	Diet effective now, Starting S
	Diet(s): Dysphagia
	Solid Consistency: National Dysphagia Diet 2-Dysphagia
	Mechanically Altered
	Advance Diet as Tolerated?
	Liquid Consistency:
	Fluid Restriction:
	Foods to Avoid:
[] Diet	Diet effective now, Starting S
	Diet(s):
	Advance Diet as Tolerated?
	Liquid Consistency:
	Fluid Restriction:
	Foods to Avoid:
IV	
IV Fluids (Single Response)	
() sodium chloride 0.9 % infusion	intravenous, continuous
() dextrose 5%-0.9% sodium chloride infusion	intravenous, continuous
() sodium chloride 0.45 % infusion	intravenous, continuous
IV Fluids with Potassium (Single Response)	
() dextrose 5 % and sodium chloride 0.9 % with potassium	intravenous, at 100 mL/hr, continuous
chloride 20 mEq/L infusion	**************************************
() sodium chloride 0.9 % with potassium chloride 20 mEq/L	intravenous, continuous
infusion	
Peripheral IV Access	
[X] Initiate and maintain IV	
[X] Insert peripheral IV	Routine, Once
[X] sodium chloride 0.9 % flush	10 mL, intravenous, every 12 hours scheduled
[X] sodium chloride 0.9 % flush	10 mL, intravenous, PRN, line care
[A] Socialii Gilonae 0.3 /6 ilasii	TO THE, HILLANGHOUS, I THN, IIIIC CAIC
Medications	
INICUICATIONS	
Consult Pharmacy - Polypharmacy	
[] Pharmacy consult to complete polypharmacy review	Routine, Until discontinued, Starting S
Medications	
[] traMADol (ULTRAM) tablet	50 mg, oral, 2 times daily
acetaminophen (TYLENOL) tablet	650 mg, oral, every 6 hours PRN, mild pain (score 1-3)
Other Medications	

[] diphenhydrAMINE (BENADRYL) tablet	25 mg, oral, once, For 1 Doses Administer prior to IVIG (Pre-Med)
[] acetaminophen (TYLENOL) tablet	325 mg, oral, once, For 1 Doses Administer prior to IVIG (Pre-Med)
[] IVIG (GAMUNEX-C) 10 % solution	600 mg/kg, intravenous, daily, For 4 Days Initiate infusion at 30 mL/hr for 60 minutes then double rate every 60 minutes as tolerated to a goal rate of 120 mL/hr. The patient is not tolerating the infusion if they develop headache, flushing, itching, rash, nausea & vomiting, muscle pain, tachycardia (heart rate >100 BPM), a temperature elevation of 1.8 degrees Fahrenheit, hypotension (SBP < 90 mmHg), hypertension (SBP > 180 mmHg), chills, problems breathing, or chest tightness. Administer if immunoglobulin A level is within normal range.
Insomnia: For Patients LESS than 70 years old (Single	Response)
() zolpidem (AMBIEN) tablet	5 mg, oral, nightly PRN, sleep
() ramelteon (ROZEREM) tablet	8 mg, oral, nightly PRN, sleep
Insomnia: For Patients GREATER than or EQUAL to 70	
() ramelteon (ROZEREM) tablet	8 mg, oral, nightly PRN, sleep
VTE	
following medical conditions: Patient already adequately anticoagulated CHF, MI, lung veins, cancer, sepsis, obesity, previous stroke, rheumators.	be addressed. In or more of the following medical conditions: One or more of the graph of the gr
() Low Risk of DVT	
[] Low Risk (Single Response)	
() Low risk of VTE	Routine, Once Low risk: Due to low risk, no VTE prophylaxis is needed. Will encourgae early ambulation
() Moderate Risk of DVT - Surgical	
Address pharmacologic prophylaxis by selecting one or pharmacologic prophylaxis is contraindicated.	f the following. Mechanical prophylaxis is optional unless

Routine, Once

Moderate Risk
Moderate risk of VTE

Patient (Single Response) () Patient is currently receiving therapeutic anticoagulation	Routine, Once
() T allone to carrottly receiving therapeans anticoagaidien	No pharmacologic VTE prophylaxis because: patient is already on therapeutic anticoagulation for other indication. Therapy for the following:
() Contraindications exist for pharmacologic prophylaxis	Routine, Once No pharmacologic VTE prophylaxis due to the following contraindication(s):
() enoxaparin (LOVENOX) injection (Single Response)	
() enoxaparin (LOVENOX) syringe	40 mg, subcutaneous, daily at 0600 (time critical), Starting S+1
() enoxaparin (LOVENOX) syringe - For Patients with CrCL LESS than 30 mL/min	30 mg, subcutaneous, daily at 0600 (time critical), Starting S+1 For Patients with CrCL LESS than 30 mL/min
() enoxaparin (LOVENOX) syringe - For Patients weight between 100-139 kg and CrCl GREATER than 30 mL/min	30 mg, subcutaneous, 2 times daily at 0600, 1800 (time critical), Starting S+1 For Patients weight between 100-139 kg and CrCl GREATER than 30 mL/min
() enoxaparin (LOVENOX) syringe - For Patients weight 140 kg or GREATER and CrCl GREATER than 30 mL/min	40 mg, subcutaneous, 2 times daily at 0600, 1800 (time critical), Starting S+1 For Patient weight of 140 kg or GREATER and CrCl GREATER than 30 mL/min
() fondaparinux (ARIXTRA) injection	2.5 mg, subcutaneous, daily, Starting S+1 If the patient does not have a history of or suspected case of Heparin-Induced Thrombocytopenia (HIT) do NOT order this medication. Contraindicated in patients LESS than 50kg, prior to surgery/invasive procedure, or CrCl LESS than 30 mL/min. This patient has a history of or suspected case of Heparin-Induced Thrombocytopenia (HIT):
() heparin (porcine) injection	5,000 Units, subcutaneous, every 8 hours, S+1 at 6:00 AM
 heparin (porcine) injection (Recommended for patients with high risk of bleeding, e.g. weight < 50kg and age > 75yrs) 	5,000 Units, subcutaneous, every 12 hours, S+1 at 6:00 AM Recommended for patients with high risk of bleeding, e.g. weight LESS than 50kg and age GREATER than 75yrs.
() warfarin (COUMADIN) tablet	oral, daily at 1700 (time critical), Starting S+1 Indication:
() Pharmacy consult to manage warfarin (COUMADIN)	STAT, Until discontinued, Starting S Indication:
Mechanical Prophylaxis (Single Response)	
() Contraindications exist for mechanical prophylaxis	Routine, Once No mechanical VTE prophylaxis due to the following contraindication(s):
() Place/Maintain sequential compression device continuous	Routine, Continuous
() Place sequential compression device and antiembolic stockings	"And" Linked Panel
[] Place/Maintain sequential compression device continuous	Routine, Continuous
[] Place antiembolic stockings	Routine, Once
Moderate Risk of DVT - Non-Surgical Address pharmacologic prophylaxis by selecting one of the follo pharmacologic prophylaxis is contraindicated.	owing. Mechanical prophylaxis is optional unless
Moderate Risk	
Moderate risk of VTE	Routine, Once

() Patient is currently receiving therapeutic anticoagulation	Routine, Once No pharmacologic VTE prophylaxis because: patient is already on therapeutic anticoagulation for other indication. Therapy for the following:
() Contraindications exist for pharmacologic prophylaxis	Routine, Once No pharmacologic VTE prophylaxis due to the following contraindication(s):
() enoxaparin (LOVENOX) injection (Single Response)	
() enoxaparin (LOVENOX) syringe	40 mg, subcutaneous, daily at 1700 (time critical), Starting S
() enoxaparin (LOVENOX) syringe - For Patients with CrCL LESS than 30 mL/min	30 mg, subcutaneous, daily at 1700 (time critical), Starting S For Patients with CrCL LESS than 30 mL/min
() enoxaparin (LOVENOX) syringe - For Patients weight between 100-139 kg and CrCl GREATER than 30 mL/min	30 mg, subcutaneous, 2 times daily, Starting S For Patients weight between 100-139 kg and CrCl GREATER than 30 mL/min
() enoxaparin (LOVENOX) syringe - For Patients weight 140 kg or GREATER and CrCl GREATER than 30 mL/min	40 mg, subcutaneous, 2 times daily, Starting S For Patients weight 140 kg or GREATER and CrCl GREATER than 30 mL/min
() fondaparinux (ARIXTRA) injection	2.5 mg, subcutaneous, daily If the patient does not have a history of or suspected case of Heparin-Induced Thrombocytopenia (HIT), do NOT order this medication. Contraindicated in patients LESS than 50kg, prior to surgery/invasive procedure, or CrCl LESS than 30 mL/min This patient has a history of or suspected case of Heparin-Induced Thrombocytopenia (HIT):
() heparin (porcine) injection	5,000 Units, subcutaneous, every 8 hours
() heparin (porcine) injection (Recommended for patients with high risk of bleeding, e.g. weight < 50kg and age > 75yrs)	5,000 Units, subcutaneous, every 12 hours Recommended for patients with high risk of bleeding, e.g. weight LESS than 50kg and age GREATER than 75yrs.
() warfarin (COUMADIN) tablet	oral, daily at 1700 (time critical) Indication:
() Pharmacy consult to manage warfarin (COUMADIN)	STAT, Until discontinued, Starting S Indication:
[] Mechanical Prophylaxis (Single Response)	
() Contraindications exist for mechanical prophylaxis	Routine, Once No mechanical VTE prophylaxis due to the following contraindication(s):
() Place/Maintain sequential compression device continuous	Routine, Continuous
() Place sequential compression device and antiembolic stockings	"And" Linked Panel
[] Place/Maintain sequential compression device continuous	Routine, Continuous
[] Place antiembolic stockings	Routine, Once
) High Risk of DVT - Surgical	
Address both pharmacologic and mechanical prophylaxis by or	rdering from Pharmacological and Mechanical Prophylaxis.
[] High Risk	
[] High risk of VTE	Routine, Once
[] High Risk Pharmacological Prophylaxis - Surgical Patient (Single Response)	
() Patient is currently receiving therapeutic anticoagulation	Routine, Once No pharmacologic VTE prophylaxis because: patient is already on therapeutic anticoagulation for other indication. Therapy for the following:
() Contraindications exist for pharmacologic prophylaxis	Routine, Once No pharmacologic VTE prophylaxis due to the following contraindication(s):
() enoxaparin (LOVENOX) injection (Single Response)	

() enoxaparin (LOVENOX) syringe	40 mg, subcutaneous, daily at 0600 (time critical), Starting S+1
() enoxaparin (LOVENOX) syringe - For Patients with CrCL LESS than 30 mL/min	30 mg, subcutaneous, daily at 0600 (time critical), Starting S+1
() enoxaparin (LOVENOX) syringe - For Patients weight between 100-139 kg and CrCl GREATER than 30 mL/min	For Patients with CrCL LESS than 30 mL/min 30 mg, subcutaneous, 2 times daily at 0600, 1800 (time critical), Starting S+1 For Patients weight between 100-139 kg and CrCl GREATER than 30 mL/min
() enoxaparin (LOVENOX) syringe - For Patients weight 140 kg or GREATER and CrCl GREATER than 30 mL/min	40 mg, subcutaneous, 2 times daily at 0600, 1800 (time critical), Starting S+1 For Patients weight 140 kg or GREATER and CrCl GREATER than 30 mL/min
() fondaparinux (ARIXTRA) injection	2.5 mg, subcutaneous, daily, Starting S+1 If the patient does not have a history or suspected case of Heparin-Induced Thrombocytopenia (HIT) do NOT order this medication. Contraindicated in patients LESS than 50kg, prior to surgery/invasive procedure, or CrCl LESS than 30 mL/min. This patient has a history of or suspected case of Heparin-Induced Thrombocytopenia (HIT):
() heparin (porcine) injection	5,000 Units, subcutaneous, every 8 hours, S+1 at 6:00 AM
 () heparin (porcine) injection (Recommended for patients with high risk of bleeding, e.g. weight < 50kg and age > 75yrs) 	5,000 Units, subcutaneous, every 12 hours, S+1 at 6:00 AM Recommended for patients with high risk of bleeding, e.g. weight LESS than 50kg and age GREATER than 75yrs.
() warfarin (COUMADIN) tablet	oral, daily at 1700 (time critical), Starting S+1 Indication:
() Pharmacy consult to manage warfarin (COUMADIN)	STAT, Until discontinued, Starting S Indication:
[] Mechanical Prophylaxis (Single Response)	
() Contraindications exist for mechanical prophylaxis	Routine, Once No mechanical VTE prophylaxis due to the following contraindication(s):
() Place/Maintain sequential compression device continuous	Routine, Continuous
() Place sequential compression device and antiembolic stockings	"And" Linked Panel
[] Place/Maintain sequential compression device continuous	Routine, Continuous
[] Place antiembolic stockings	Routine, Once
High Risk of DVT - Non-Surgical Address both pharmacologic and mechanical prophylaxis by ordinary.	dering from Pharmacological and Mechanical Prophylaxis.
[] High Risk	
[] High risk of VTE[] High Risk Pharmacological Prophylaxis - Non-Surgical Patient (Single Response)	Routine, Once
() Patient is currently receiving therapeutic anticoagulation	Routine, Once No pharmacologic VTE prophylaxis because: patient is already on therapeutic anticoagulation for other indication. Therapy for the following:
() Contraindications exist for pharmacologic prophylaxis	Routine, Once No pharmacologic VTE prophylaxis due to the following contraindication(s):
() enoxaparin (LOVENOX) injection (Single Response)	
() enoxaparin (LOVENOX) syringe	40 mg, subcutaneous, daily at 1700 (time critical), Starting S
() enoxaparin (LOVENOX) syringe - For Patients with CrCL LESS than 30 mL/min	30 mg, subcutaneous, daily at 1700 (time critical), Starting S For Patients with CrCL LESS than 30 mL/min

() enoxaparin (LOVENOX) syringe - For Patients weight between 100-139 kg and CrCl GREATER than 30 mL/min	30 mg, subcutaneous, 2 times daily, Starting S For Patients weight between 100-139 kg and CrCl GREATER than 30 mL/min
 enoxaparin (LOVENOX) syringe - For Patients weight 140 kg or GREATER and CrCl GREATER than 30 mL/min 	40 mg, subcutaneous, 2 times daily, Starting S For Patients weight 140 kg or GREATER and CrCl GREATER than 30 mL/min
() fondaparinux (ARIXTRA) injection	2.5 mg, subcutaneous, daily If the patient does not have a history of or suspected case of Heparin-Induced Thrombocytopenia (HIT) do NOT order this medication. Contraindicated in patients LESS than 50kg, prior to surgery/invasive procedure, or CrCI LESS than 30 mL/min. This patient has a history of or suspected case of Heparin-Induced Thrombocytopenia (HIT):
() heparin (porcine) injection	5,000 Units, subcutaneous, every 8 hours
() heparin (porcine) injection (Recommended for patients with high risk of bleeding, e.g. weight < 50kg and age > 75yrs)	5,000 Units, subcutaneous, every 12 hours Recommended for patients with high risk of bleeding, e.g. weight LESS than 50kg and age GREATER than 75yrs.
() warfarin (COUMADIN) tablet	oral, daily at 1700 (time critical) Indication:
() Pharmacy consult to manage warfarin (COUMADIN)	STAT, Until discontinued, Starting S Indication:
[] Mechanical Prophylaxis (Single Response)	
() Contraindications exist for mechanical prophylaxis	Routine, Once No mechanical VTE prophylaxis due to the following contraindication(s):
() Place/Maintain sequential compression device continuous	Routine, Continuous
() Place sequential compression device and antiembolic stockings	"And" Linked Panel
[] Place/Maintain sequential compression device continuous	Routine, Continuous
[] Place antiembolic stockings	Routine, Once
) High Risk of DVT - Surgical (Hip/Knee)	
Address both pharmacologic and mechanical prophylaxis by or	dering from Pharmacological and Mechanical Prophylaxis.
[] High Risk	
[] High risk of VTE	Routine, Once
[] High Risk Pharmacological Prophylaxis - Hip or Knee (Arthroplasty) Surgical Patient (Single Response)	
() Patient is currently receiving therapeutic anticoagulation	Routine, Once No pharmacologic VTE prophylaxis because: patient is already on therapeutic anticoagulation for other indication. Therapy for the following:
() Contraindications exist for pharmacologic prophylaxis	Routine, Once No pharmacologic VTE prophylaxis due to the following contraindication(s):
() apixaban (ELIQUIS) tablet	2.5 mg, oral, every 12 hours, Starting S+1 Indications:
() aspirin chewable tablet	162 mg, oral, daily, Starting S+1
() aspirin (ECOTRIN) enteric coated tablet	162 mg, oral, daily, Starting S+1
() enoxaparin (LOVENOX) injection (Single Response)	40
() enoxaparin (LOVENOX) syringe - hip arthoplasty	40 mg, subcutaneous, daily at 0600 (time critical), Starting S+1
() enoxaparin (LOVENOX) syringe - knee arthroplasty	30 mg, subcutaneous, 2 times daily at 0600, 1800 (time critical), Starting S+1
() enoxaparin (LOVENOX) syringe - For Patients with CrCL LESS than 30 mL/min - knee/hip arthroplasty	30 mg, subcutaneous, daily at 0600 (time critical), Starting S+1 For Patients with CrCL LESS than 30 mL/min.

() enoxaparin (LOVENOX) syringe - For Patients weight between 100-139 kg and CrCl GREATER than 30 mL/min	critical), Starting S+1 For Patients weight between 100-139 kg and CrCl GREATER than 30 mL/min.
() enoxaparin (LOVENOX) syringe - For Patients weight 140 kg or GREATER and CrCl GREATER than 30 mL/min	40 mg, subcutaneous, 2 times daily at 0600, 1800 (time critical), Starting S+1 For Patients weight 140 kg or GREATER and CrCl GREATER than 30 mL/min
() fondaparinux (ARIXTRA) injection	2.5 mg, subcutaneous, daily, Starting S+1 If the patient does not have a history or suspected case of Heparin-Induced Thrombocytopenia (HIT) do NOT order this medication. Contraindicated in patients LESS than 50kg, prior to surgery/invasive procedure, or CrCl LESS than 30 mL/min This patient has a history of or suspected case of Heparin-Induced Thrombocytopenia (HIT):
() heparin (porcine) injection	5,000 Units, subcutaneous, every 8 hours, S+1 at 6:00 AM
 () heparin (porcine) injection (Recommended for patients with high risk of bleeding, e.g. weight < 50kg and age > 75yrs) 	5,000 Units, subcutaneous, every 12 hours, S+1 at 6:00 AM Recommended for patients with high risk of bleeding, e.g. weight LESS than 50kg and age GREATER than 75yrs.
() rivaroxaban (XARELTO) tablet for hip or knee arthroplasty planned during this admission	10 mg, oral, daily at 0600 (time critical), Starting S+1 To be Given on Post Op Day 1. Indications:
() warfarin (COUMADIN) tablet	oral, daily at 1700 (time critical), Starting S+1 Indication:
() Pharmacy consult to manage warfarin (COUMADIN)	STAT, Until discontinued, Starting S Indication:
Mechanical Prophylaxis (Single Response)	
() Contraindications exist for mechanical prophylaxis	Routine, Once No mechanical VTE prophylaxis due to the following contraindication(s):
() Place/Maintain sequential compression device continuous	Routine, Continuous
() Place sequential compression device and antiembolic stockings	"And" Linked Panel
[] Place/Maintain sequential compression device continuous	Routine, Continuous
[] Place antiembolic stockings	Routine, Once

DVT Risk and Prophylaxis Tool (Single Response)

Low Risk Definition Moderate Risk Definition

Pharmacologic prophylaxis must be addressed. Mechanical prophylaxis is optional unless pharmacologic is contraindicated. High Risk Definition

Both pharmacologic AND mechanical prophylaxis must be addressed.

Age less than 60 years and NO other VTE risk factors One or more of the following medical conditions: One or more of the following medical conditions:

Patient already adequately anticoagulated CHF, MI, lung disease, pneumonia, active inflammation, dehydration, varicose veins, cancer, sepsis, obesity, previous stroke, rheumatologic disease, sickle cell disease, leg swelling, ulcers, venous stasis and nephrotic syndrome Thrombophilia (Factor V Leiden, prothrombin variant mutations, anticardiolipin antibody syndrome; antithrombin, protein C or protein S deficiency; hyperhomocysteinemia; myeloproliferative disorders)

Age 60 and above Severe fracture of hip, pelvis or leg

Central line Acute spinal cord injury with paresis

History of DVT or family history of VTE Multiple major traumas

Anticipated length of stay GREATER than 48 hours Abdominal or pelvic surgery for CANCER

Less than fully and independently ambulatory Acute ischemic stroke

Estrogen therapy History of PE

Moderate or major surgery (not for cancer)

Major surgery within 3 months of admission

[] Low Risk (Single Response)	
() Low risk of VTE	Routine, Once Low risk: Due to low risk, no VTE prophylaxis is needed. Will encourgae early ambulation
() Moderate Risk of DVT - Surgical	Will choodigae carry ambulation
Address pharmacologic prophylaxis by selecting one of the follopharmacologic prophylaxis is contraindicated.	wing. Mechanical prophylaxis is optional unless
[] Moderate Risk	
[] Moderate risk of VTE	Routine, Once
[] Moderate Risk Pharmacological Prophylaxis - Surgical Patient (Single Response)	
() Patient is currently receiving therapeutic anticoagulation	Routine, Once No pharmacologic VTE prophylaxis because: patient is already on therapeutic anticoagulation for other indication. Therapy for the following:
() Contraindications exist for pharmacologic prophylaxis	Routine, Once No pharmacologic VTE prophylaxis due to the following contraindication(s):
() enoxaparin (LOVENOX) injection (Single Response)	
() enoxaparin (LOVENOX) syringe	40 mg, subcutaneous, daily at 0600 (time critical), Starting S+1
() enoxaparin (LOVENOX) syringe - For Patients with CrCL LESS than 30 mL/min	30 mg, subcutaneous, daily at 0600 (time critical), Starting S+1 For Patients with CrCL LESS than 30 mL/min
() enoxaparin (LOVENOX) syringe - For Patients weight between 100-139 kg and CrCl GREATER than 30 mL/min	30 mg, subcutaneous, 2 times daily at 0600, 1800 (time critical), Starting S+1 For Patients weight between 100-139 kg and CrCl GREATER than 30 mL/min
() enoxaparin (LOVENOX) syringe - For Patients weight 140 kg or GREATER and CrCl GREATER than 30 mL/min	40 mg, subcutaneous, 2 times daily at 0600, 1800 (time critical), Starting S+1 For Patients weight 140 kg or GREATER and CrCl GREATER than 30 mL/min
() fondaparinux (ARIXTRA) injection	2.5 mg, subcutaneous, daily, Starting S+1 If the patient does not have a history of or suspected case of Heparin-Induced Thrombocytopenia (HIT) do NOT order this medication. Contraindicated in patients LESS than 50kg, prior to surgery/invasive procedure, or CrCl LESS than 30 mL/min. This patient has a history of or suspected case of Heparin-Induced Thrombocytopenia (HIT):
() heparin (porcine) injection	5,000 Units, subcutaneous, every 8 hours, S+1 at 6:00 AM
() heparin (porcine) injection (Recommended for patients with high risk of bleeding, e.g. weight < 50kg and age > 75yrs)	5,000 Units, subcutaneous, every 12 hours, S+1 at 6:00 AM Recommended for patients with high risk of bleeding, e.g. weight LESS than 50kg and age GREATER than 75yrs.
() warfarin (COUMADIN) tablet	oral, daily at 1700 (time critical), Starting S+1 Indication:
() Pharmacy consult to manage warfarin (COUMADIN)	STAT, Until discontinued, Starting S Indication:
() Moderate Risk of DVT - Non-Surgical	
Address pharmacologic prophylaxis by selecting one of the follo pharmacologic prophylaxis is contraindicated.	wing. Mechanical prophylaxis is optional unless
[] Moderate Risk	
[] Moderate risk of VTE	Routine, Once
[] Moderate Risk Pharmacological Prophylaxis - Non-Surgical Patient (Single Response)	

() Patient is currently receiving therapeutic anticoagulation	Routine, Once No pharmacologic VTE prophylaxis because: patient is already on therapeutic anticoagulation for other indication. Therapy for the following:
() Contraindications exist for pharmacologic prophylaxis	Routine, Once No pharmacologic VTE prophylaxis due to the following contraindication(s):
() enoxaparin (LOVENOX) injection (Single Response)	
() enoxaparin (LOVENOX) syringe	40 mg, subcutaneous, daily at 1700 (time critical), Starting S+1
() enoxaparin (LOVENOX) syringe - For Patients with CrCL LESS than 30 mL/min	30 mg, subcutaneous, daily at 1700 (time critical), Starting S+1 For Patients with CrCL LESS than 30 mL/min
() enoxaparin (LOVENOX) syringe - For Patients weight between 100-139 kg and CrCl GREATER than 30 mL/min	30 mg, subcutaneous, every 12 hours at 0900, 2100 (time critical), Starting S+1 For Patients weight between 100-139 kg and CrCl GREATER than 30 mL/min
() enoxaparin (LOVENOX) syringe - For Patients weight 140 kg or GREATER and CrCl GREATER than 30 mL/min	40 mg, subcutaneous, every 12 hours at 0900, 2100 (time critical), Starting S+1 For Patients weight 140 kg or GREATER and CrCl GREATER than 30 mL/min
() fondaparinux (ARIXTRA) injection	2.5 mg, subcutaneous, daily If the patient does not have a history of or suspected case of Heparin-Induced Thrombocytopenia (HIT), do NOT order this medication. Contraindicated in patients LESS than 50kg, prior to surgery/invasive procedure, or CrCl LESS than 30 mL/min This patient has a history of or suspected case of Heparin-Induced Thrombocytopenia (HIT):
() heparin (porcine) injection	5,000 Units, subcutaneous, every 8 hours
 () heparin (porcine) injection (Recommended for patients with high risk of bleeding, e.g. weight < 50kg and age > 75yrs) 	5,000 Units, subcutaneous, every 12 hours Recommended for patients with high risk of bleeding, e.g. weight LESS than 50kg and age GREATER than 75yrs.
() warfarin (COUMADIN) tablet	oral, daily at 1700 (time critical) Indication:
() Pharmacy consult to manage warfarin (COUMADIN)	STAT, Until discontinued, Starting S Indication:
() High Risk of DVT - Surgical	
Address both pharmacologic and mechanical prophylaxis by ord	dering from Pharmacological and Mechanical Prophylaxis.
[] High Risk	
[] High risk of VTE[] High Risk Pharmacological Prophylaxis - Surgical Patient (Single Response)	Routine, Once
() Patient is currently receiving therapeutic anticoagulation	Routine, Once No pharmacologic VTE prophylaxis because: patient is already on therapeutic anticoagulation for other indication. Therapy for the following:
() Contraindications exist for pharmacologic prophylaxis	Routine, Once No pharmacologic VTE prophylaxis due to the following contraindication(s):
() enoxaparin (LOVENOX) injection (Single Response)	
() enoxaparin (LOVENOX) syringe	40 mg, subcutaneous, daily at 0600 (time critical), Starting S+1
() enoxaparin (LOVENOX) syringe - For Patients with CrCL LESS than 30 mL/min	30 mg, subcutaneous, daily at 0600 (time critical), Starting S+1 For Patients with CrCL LESS than 30 mL/min
() enoxaparin (LOVENOX) syringe - For Patients weight between 100-139 kg and CrCl GREATER than 30 mL/min	30 mg, subcutaneous, 2 times daily at 0600, 1800 (time critical), Starting S+1 For Patients weight between 100-139 kg and CrCl GREATER than 30 mL/min

() warfarin (COUMADIN) tablet	oral, daily at 1700 (time critical) Indication:
with high risk of bleeding, e.g. weight < 50kg and age > 75yrs)	Recommended for patients with high risk of bleeding, e.g. weight LESS than 50kg and age GREATER than 75yrs.
() heparin (porcine) injection (Recommended for patients	5,000 Units, subcutaneous, every 12 hours
() heparin (porcine) injection	Heparin-Induced Thrombocytopenia (HIT): 5,000 Units, subcutaneous, every 8 hours
	This patient has a history of or suspected case of
	50kg, prior to surgery/invasive procedure, or CrCl LESS than 30 mL/min.
	this medication. Contraindicated in patients LESS than
	of Heparin-Induced Thrombocytopenia (HIT) do NOT order
() fondaparinux (ARIXTRA) injection	2.5 mg, subcutaneous, daily If the patient does not have a history of or suspected case
mL/min	For Patients weight 140 kg or GREATER and CrCl GREATER than 30 mL/min
140 kg or GREATER and CrCl GREATER than 30	critical)
() enoxaparin (LOVENOX) syringe - For Patients weight	GREATER than 30 mL/min 40 mg, subcutaneous, every 12 hours at 0900, 2100 (time
mL/min	For Patients weight between 100-139 kg and CrCl
() enoxaparin (LOVENOX) syringe - For Patients weight between 100-139 kg and CrCl GREATER than 30	30 mg, subcutaneous, every 12 hours at 0900, 2100 (time critical), Starting S+1
LESS than 30 mL/min	For Patients with CrCL LESS than 30 mL/min
() enoxaparin (LOVENOX) syringe - For Patients with CrCL	30 mg, subcutaneous, daily, Starting S+1
() enoxaparin (LOVENOX) injection (Single Response)() enoxaparin (LOVENOX) syringe	40 mg, subcutaneous, daily, Starting S+1
() an arranging (I OVENOV) in its 1/2 (O) I D	contraindication(s):
() Contramidications exist for pharmacologic prophylaxis	No pharmacologic VTE prophylaxis due to the following
() Contraindications exist for pharmacologic prophylaxis	Therapy for the following: Routine, Once
	already on the apeutic anticoagulation for other indication.
() . a.c. in o can only reconstruction and condition	No pharmacologic VTE prophylaxis because: patient is
Patient (Single Response) () Patient is currently receiving therapeutic anticoagulation	Routine, Once
[] High Risk Pharmacological Prophylaxis - Non-Surgical	
[] High risk of VTE	Routine, Once
[] High Risk	
Address both pharmacologic and mechanical prophylaxis by or	rdering from Pharmacological and Mechanical Prophylaxis.
High Risk of DVT - Non-Surgical	
	Indication:
() Pharmacy consult to manage warfarin (COUMADIN)	STAT, Until discontinued, Starting S
() warfarin (COUMADIN) tablet	oral, daily at 1700 (time critical), Starting S+1 Indication:
() workering (COLIMADIAN) to block	weight LESS than 50kg and age GREATER than 75yrs.
75yrs)	Recommended for patients with high risk of bleeding, e.g.
() heparin (porcine) injection (Recommended for patients with high risk of bleeding, e.g. weight < 50kg and age >	5,000 Units, subcutaneous, every 12 hours, S+1 at 6:00 AM
	AM
() heparin (porcine) injection	5,000 Units, subcutaneous, every 8 hours, S+1 at 6:00
	This patient has a history of or suspected case of Heparin-Induced Thrombocytopenia (HIT):
	50kg, prior to surgery/invasive procedure, or CrCl LESS than 30 mL/min.
	this medication. Contraindicated in patients LESS than
	Heparin-Induced Thrombocytopenia (HIT) do NOT order
() fondaparinux (ARIXTRA) injection	2.5 mg, subcutaneous, daily, Starting S+1 If the patient does not have a history or suspected case of
	GREATER than 30 mL/min
140 kg or GREATER and CrCl GREATER than 30 mL/min	critical), Starting S+1 For Patients weight 140 kg or GREATER and CrCl
140 kg or GBEATER and CruitGBEATER than 30	Critical) Starting S±1

() Pharmacy consult to manage warfarin (COUMADIN) STAT, Until discontinued, Starting S Indication:
High Risk of DVT - Surgical (Hip/Knee)	
	l prophylaxis by ordering from Pharmacological and Mechanical Prophylaxis.
[] High Risk	
[] High risk of VTE	Routine, Once
[] High Risk Pharmacological Prophylaxis - (Arthroplasty) Surgical Patient (Single Re	sponse)
() Patient is currently receiving therapeution	No pharmacologic VTE prophylaxis because: patient is already on therapeutic anticoagulation for other indication. Therapy for the following:
() Contraindications exist for pharmacolog	c prophylaxis Routine, Once No pharmacologic VTE prophylaxis due to the following contraindication(s):
() apixaban (ELIQUIS) tablet	2.5 mg, oral, every 12 hours, Starting S+1 Indications:
() aspirin chewable tablet	162 mg, oral, daily, Starting S+1
() aspirin (ECOTRIN) enteric coated table() enoxaparin (LOVENOX) injection (Single	162 mg, oral, daily, Starting S+1 Response)
() enoxaparin (LOVENOX) syringe - hip a	<u> </u>
() enoxaparin (LOVENOX) syringe - knee	arthroplasty 30 mg, subcutaneous, 2 times daily at 0600, 1800 (time critical), Starting S+1
() enoxaparin (LOVENOX) syringe - For LESS than 30 mL/min - knee/hip arthro	
() enoxaparin (LOVENOX) syringe - Fo between 100-139 kg and CrCl GREAT mL/min	Patients weight 30 mg, subcutaneous, 2 times daily at 0600, 1800 (time
() enoxaparin (LOVENOX) syringe - For 140 kg or GREATER and CrCl GREATML/min	
() fondaparinux (ARIXTRA) injection	2.5 mg, subcutaneous, daily, Starting S+1 If the patient does not have a history or suspected case of Heparin-Induced Thrombocytopenia (HIT) do NOT order this medication. Contraindicated in patients LESS than 50kg, prior to surgery/invasive procedure, or CrCl LESS than 30 mL/min This patient has a history of or suspected case of Heparin-Induced Thrombocytopenia (HIT):
() heparin (porcine) injection	5,000 Units, subcutaneous, every 8 hours, S+1 at 6:00 AM
() heparin (porcine) injection (Recommend with high risk of bleeding, e.g. weight < 75yrs)	
() rivaroxaban (XARELTO) tablet for hip o arthroplasty planned during this admissi	knee 10 mg, oral, daily at 0600 (time critical), Starting S+1
() warfarin (COUMADIN) tablet	oral, daily at 1700 (time critical), Starting S+1 Indication:
() Pharmacy consult to manage warfarin (COUMADIN) STAT, Until discontinued, Starting S Indication:

DVT Risk and Prophylaxis Tool (Single Response)

Low Risk Definition Moderate Risk Definition

Pharmacologic prophylaxis must be addressed. Mechanical prophylaxis is optional unless pharmacologic is contraindicated. High Risk Definition

Both pharmacologic AND mechanical prophylaxis must be addressed.

Age less than 60 years and NO other VTE risk factors One or more of the following medical conditions: One or more of the following medical conditions:

Patient already adequately anticoagulated CHF, MI, lung disease, pneumonia, active inflammation, dehydration, varicose veins, cancer, sepsis, obesity, previous stroke, rheumatologic disease, sickle cell disease, leg swelling, ulcers, venous stasis and nephrotic syndrome Thrombophilia (Factor V Leiden, prothrombin variant mutations, anticardiolipin antibody syndrome; antithrombin, protein C or protein S deficiency; hyperhomocysteinemia; myeloproliferative disorders)

Age 60 and above Severe fracture of hip, pelvis or leg

Central line Acute spinal cord injury with paresis

History of DVT or family history of VTE Multiple major traumas

Anticipated length of stay GREATER than 48 hours Abdominal or pelvic surgery for CANCER

Less than fully and independently ambulatory Acute ischemic stroke

Estrogen therapy History of PE

Moderate or major surgery (not for cancer)

Major surgery within 3 months of admission

() Low Risk of DVT	
[] Low Risk (Single Response)	
() Low risk of VTE	Routine, Once Low risk: Due to low risk, no VTE prophylaxis is needed. Will encourgae early ambulation
() Moderate Risk of DVT - Surgical	
Address pharmacologic prophylaxis by selecting one of the follopharmacologic prophylaxis is contraindicated.	owing. Mechanical prophylaxis is optional unless
[] Moderate Risk	
[] Moderate risk of VTE	Routine, Once
[] Moderate Risk Pharmacological Prophylaxis - Surgical Patient (Single Response)	
() Patient is currently receiving therapeutic anticoagulation	Routine, Once No pharmacologic VTE prophylaxis because: patient is already on therapeutic anticoagulation for other indication. Therapy for the following:
() Contraindications exist for pharmacologic prophylaxis	Routine, Once No pharmacologic VTE prophylaxis due to the following contraindication(s):
() enoxaparin (LOVENOX) injection (Single Response)	
() enoxaparin (LOVENOX) syringe	40 mg, subcutaneous, daily at 0600 (time critical), Starting S+1
() enoxaparin (LOVENOX) syringe - For Patients with CrCL LESS than 30 mL/min	30 mg, subcutaneous, daily at 0600 (time critical), Starting S+1 For Patients with CrCL LESS than 30 mL/min
() enoxaparin (LOVENOX) syringe - For Patients weight between 100-139 kg and CrCl GREATER than 30 mL/min	30 mg, subcutaneous, 2 times daily at 0600, 1800 (time critical), Starting S+1 For Patients weight between 100-139 kg and CrCl GREATER than 30 mL/min
() enoxaparin (LOVENOX) syringe - For Patients weight 140 kg or GREATER and CrCl GREATER than 30 mL/min	40 mg, subcutaneous, 2 times daily at 0600, 1800 (time critical), Starting S+1 For Patient weight of 140 kg or GREATER and CrCl GREATER than 30 mL/min
() fondaparinux (ARIXTRA) injection	2.5 mg, subcutaneous, daily, Starting S+1 If the patient does not have a history of or suspected case of Heparin-Induced Thrombocytopenia (HIT) do NOT order this medication. Contraindicated in patients LESS than 50kg, prior to surgery/invasive procedure, or CrCl LESS than 30 mL/min. This patient has a history of or suspected case of Heparin-Induced Thrombocytopenia (HIT):

() heparin (porcine) injection	5,000 Units, subcutaneous, every 8 hours, S+1 at 6:00 AM
() heparin (porcine) injection (Recommended for patients	5,000 Units, subcutaneous, every 12 hours, S+1 at 6:00
with high risk of bleeding, e.g. weight < 50kg and age >	AM
75yrs)	Recommended for patients with high risk of bleeding, e.g. weight LESS than 50kg and age GREATER than 75yrs.
() warfarin (COUMADIN) tablet	oral, daily at 1700 (time critical), Starting S+1 Indication:
() Pharmacy consult to manage warfarin (COUMADIN)	STAT, Until discontinued, Starting S Indication:
[] Mechanical Prophylaxis (Single Response)	
() Contraindications exist for mechanical prophylaxis	Routine, Once
	No mechanical VTE prophylaxis due to the following contraindication(s):
() Place/Maintain sequential compression device continuous	Routine, Continuous
 Place sequential compression device and antiembolic stockings 	"And" Linked Panel
[] Place/Maintain sequential compression device continuous	Routine, Continuous
[] Place antiembolic stockings	Routine, Once
) Moderate Risk of DVT - Non-Surgical	
Address pharmacologic prophylaxis by selecting one of the follopharmacologic prophylaxis is contraindicated.	owing. Mechanical prophylaxis is optional unless
Moderate Risk	
[] Moderate risk of VTE	Routine, Once
[] Moderate Risk Pharmacological Prophylaxis - Non-Surgical Patient (Single Response)	
() Patient is currently receiving therapeutic anticoagulation	Routine, Once
	No pharmacologic VTE prophylaxis because: patient is
	already on therapeutic anticoagulation for other indication.
() Contraindingtions exist for about a coloris are bulletin	Therapy for the following:
() Contraindications exist for pharmacologic prophylaxis	Routine, Once No pharmacologic VTE prophylaxis due to the following
	contraindication(s):
() enoxaparin (LOVENOX) injection (Single Response)	· /
() enoxaparin (LOVENOX) syringe	40 mg, subcutaneous, daily at 1700 (time critical), Starting
() : ((0)/[[10](0)] : [[[[[[[[[[[[[[[[[[S
() enoxaparin (LOVENOX) syringe - For Patients with CrCL LESS than 30 mL/min	30 mg, subcutaneous, daily at 1700 (time critical), Starting S
LEGS than 50 me/min	For Patients with CrCL LESS than 30 mL/min
() enoxaparin (LOVENOX) syringe - For Patients weight	30 mg, subcutaneous, 2 times daily, Starting S
between 100-139 kg and CrCl GREATER than 30 mL/min	For Patients weight between 100-139 kg and CrCl GREATER than 30 mL/min
() enoxaparin (LOVENOX) syringe - For Patients weight	40 mg, subcutaneous, 2 times daily, Starting S
140 kg or GREATER and CrCl GREATER than 30 mL/min	For Patients weight 140 kg or GREATER and CrCl GREATER than 30 mL/min
() fondaparinux (ARIXTRA) injection	2.5 mg, subcutaneous, daily
	If the patient does not have a history of or suspected case
	of Heparin-Induced Thrombocytopenia (HIT), do NOT order this medication. Contraindicated in patients LESS than
	50kg, prior to surgery/invasive procedure, or CrCl LESS
	than 30 mL/min
	This patient has a history of or suspected case of
	Heparin-Induced Thrombocytopenia (HIT):
() heparin (porcine) injection	5,000 Units, subcutaneous, every 8 hours
() heparin (porcine) injection (Recommended for patients	5,000 Units, subcutaneous, every 12 hours
with high risk of bleeding, e.g. weight < 50kg and age > 75yrs)	Recommended for patients with high risk of bleeding, e.g. weight LESS than 50kg and age GREATER than 75yrs.
() warfarin (COUMADIN) tablet	oral, daily at 1700 (time critical)
\\\\\\\\\\\\\\\\\\\\\\\\\\\\\\\\\\	Indication:

() Pharmacy consult to manage warfarin (COUMADIN)	STAT, Until discontinued, Starting S Indication:
[] Mechanical Prophylaxis (Single Response)	
() Contraindications exist for mechanical prophylaxis	Routine, Once No mechanical VTE prophylaxis due to the following contraindication(s):
() Place/Maintain sequential compression device continuous	Routine, Continuous
() Place sequential compression device and antiembolic stockings	"And" Linked Panel
[] Place/Maintain sequential compression device continuous	Routine, Continuous
[] Place antiembolic stockings	Routine, Once
) High Risk of DVT - Surgical	
Address both pharmacologic and mechanical prophylaxis by o	ordering from Pharmacological and Mechanical Prophylaxis.
[] High Risk	
[] High risk of VTE	Routine, Once
[] High Risk Pharmacological Prophylaxis - Surgical Patient (Single Response)	
() Patient is currently receiving therapeutic anticoagulation	Routine, Once No pharmacologic VTE prophylaxis because: patient is already on therapeutic anticoagulation for other indication. Therapy for the following:
() Contraindications exist for pharmacologic prophylaxis	Routine, Once No pharmacologic VTE prophylaxis due to the following contraindication(s):
() enoxaparin (LOVENOX) injection (Single Response)	
() enoxaparin (LOVENOX) syringe	40 mg, subcutaneous, daily at 0600 (time critical), Starting S+1
() enoxaparin (LOVENOX) syringe - For Patients with CrCl LESS than 30 mL/min	30 mg, subcutaneous, daily at 0600 (time critical), Starting S+1 For Patients with CrCL LESS than 30 mL/min
() enoxaparin (LOVENOX) syringe - For Patients weight between 100-139 kg and CrCl GREATER than 30 mL/min	30 mg, subcutaneous, 2 times daily at 0600, 1800 (time critical), Starting S+1 For Patients weight between 100-139 kg and CrCl GREATER than 30 mL/min
() enoxaparin (LOVENOX) syringe - For Patients weight 140 kg or GREATER and CrCl GREATER than 30 mL/min	40 mg, subcutaneous, 2 times daily at 0600, 1800 (time critical), Starting S+1 For Patients weight 140 kg or GREATER and CrCl GREATER than 30 mL/min
() fondaparinux (ARIXTRA) injection	2.5 mg, subcutaneous, daily, Starting S+1 If the patient does not have a history or suspected case of Heparin-Induced Thrombocytopenia (HIT) do NOT order this medication. Contraindicated in patients LESS than 50kg, prior to surgery/invasive procedure, or CrCl LESS than 30 mL/min. This patient has a history of or suspected case of Heparin-Induced Thrombocytopenia (HIT):
() heparin (porcine) injection	5,000 Units, subcutaneous, every 8 hours, S+1 at 6:00 AM
() heparin (porcine) injection (Recommended for patients with high risk of bleeding, e.g. weight < 50kg and age > 75yrs)	5,000 Units, subcutaneous, every 12 hours, S+1 at 6:00 AM Recommended for patients with high risk of bleeding, e.g. weight LESS than 50kg and age GREATER than 75yrs.
() warfarin (COUMADIN) tablet	oral, daily at 1700 (time critical), Starting S+1 Indication:
() Pharmacy consult to manage warfarin (COUMADIN)	STAT, Until discontinued, Starting S Indication:
[] Mechanical Prophylaxis (Single Response)	

() Contraindications exist for mechanical prophylaxis	Routine, Once No mechanical VTE prophylaxis due to the following contraindication(s):
() Place/Maintain sequential compression device continuous	Routine, Continuous
Place sequential compression device and antiembolic stockings	"And" Linked Panel
[] Place/Maintain sequential compression device continuous	Routine, Continuous
Place antiembolic stockings	Routine, Once
) High Risk of DVT - Non-Surgical	
Address both pharmacologic and mechanical prophylaxis by ord	dering from Pharmacological and Mechanical Prophylaxis.
[] High Risk	
[] High risk of VTE	Routine, Once
[] High Risk Pharmacological Prophylaxis - Non-Surgical Patient (Single Response)	
() Patient is currently receiving therapeutic anticoagulation	Routine, Once
	No pharmacologic VTE prophylaxis because: patient is already on therapeutic anticoagulation for other indication. Therapy for the following:
() Contraindications exist for pharmacologic prophylaxis	Routine, Once No pharmacologic VTE prophylaxis due to the following contraindication(s):
() enoxaparin (LOVENOX) injection (Single Response)	
() enoxaparin (LOVENOX) syringe	40 mg, subcutaneous, daily at 1700 (time critical), Starting S
() enoxaparin (LOVENOX) syringe - For Patients with CrCL LESS than 30 mL/min	30 mg, subcutaneous, daily at 1700 (time critical), Starting S For Patients with CrCL LESS than 30 mL/min
() enoxaparin (LOVENOX) syringe - For Patients weight between 100-139 kg and CrCl GREATER than 30 mL/min	30 mg, subcutaneous, 2 times daily, Starting S For Patients weight between 100-139 kg and CrCl GREATER than 30 mL/min
 enoxaparin (LOVENOX) syringe - For Patients weight 140 kg or GREATER and CrCl GREATER than 30 mL/min 	40 mg, subcutaneous, 2 times daily, Starting S For Patients weight 140 kg or GREATER and CrCl GREATER than 30 mL/min
() fondaparinux (ARIXTRA) injection	2.5 mg, subcutaneous, daily If the patient does not have a history of or suspected case of Heparin-Induced Thrombocytopenia (HIT) do NOT order this medication. Contraindicated in patients LESS than 50kg, prior to surgery/invasive procedure, or CrCl LESS than 30 mL/min. This patient has a history of or suspected case of Heparin-Induced Thrombocytopenia (HIT):
() heparin (porcine) injection	5,000 Units, subcutaneous, every 8 hours
() heparin (porcine) injection (Recommended for patients with high risk of bleeding, e.g. weight < 50kg and age > 75yrs)	5,000 Units, subcutaneous, every 12 hours Recommended for patients with high risk of bleeding, e.g. weight LESS than 50kg and age GREATER than 75yrs.
() warfarin (COUMADIN) tablet	oral, daily at 1700 (time critical) Indication:
() Pharmacy consult to manage warfarin (COUMADIN)	STAT, Until discontinued, Starting S Indication:
[] Mechanical Prophylaxis (Single Response)	
() Contraindications exist for mechanical prophylaxis	Routine, Once No mechanical VTE prophylaxis due to the following contraindication(s):
() Place/Maintain sequential compression device continuous	Routine, Continuous
() Place sequential compression device and antiembolic stockings	"And" Linked Panel
[] Place/Maintain sequential compression device	Routine, Continuous

[]	Place antiembolic stockings	Routine, Once
) Hig	h Risk of DVT - Surgical (Hip/Knee)	
	dress both pharmacologic and mechanical prophylaxis by ord	dering from Pharmacological and Mechanical Prophylaxis.
[] H	High Risk	
[]	High risk of VTE	Routine, Once
	High Risk Pharmacological Prophylaxis - Hip or Knee (Arthroplasty) Surgical Patient (Single Response)	
()	Patient is currently receiving therapeutic anticoagulation	Routine, Once No pharmacologic VTE prophylaxis because: patient is already on therapeutic anticoagulation for other indication. Therapy for the following:
()	Contraindications exist for pharmacologic prophylaxis	Routine, Once No pharmacologic VTE prophylaxis due to the following contraindication(s):
()	apixaban (ELIQUIS) tablet	2.5 mg, oral, every 12 hours, Starting S+1 Indications:
()	aspirin chewable tablet	162 mg, oral, daily, Starting S+1
()	aspirin (ECOTRIN) enteric coated tablet	162 mg, oral, daily, Starting S+1
()	enoxaparin (LOVENOX) injection (Single Response)	
()	enoxaparin (LOVENOX) syringe - hip arthoplasty	40 mg, subcutaneous, daily at 0600 (time critical), Starting $S+1$
()	enoxaparin (LOVENOX) syringe - knee arthroplasty	30 mg, subcutaneous, 2 times daily at 0600, 1800 (time critical), Starting S+1
()	enoxaparin (LOVENOX) syringe - For Patients with CrCL LESS than 30 mL/min - knee/hip arthroplasty	30 mg, subcutaneous, daily at 0600 (time critical), Starting S+1 For Patients with CrCL LESS than 30 mL/min.
()	enoxaparin (LOVENOX) syringe - For Patients weight	30 mg, subcutaneous, 2 times daily at 0600, 1800 (time
()	between 100-139 kg and CrCl GREATER than 30	critical), Starting S+1
	mL/min	For Patients weight between 100-139 kg and CrCl GREATER than 30 mL/min.
()	enoxaparin (LOVENOX) syringe - For Patients weight 140 kg or GREATER and CrCl GREATER than 30 mL/min	40 mg, subcutaneous, 2 times daily at 0600, 1800 (time critical), Starting S+1 For Patients weight 140 kg or GREATER and CrCl
		GREATER than 30 mL/min
()	fondaparinux (ARIXTRA) injection	2.5 mg, subcutaneous, daily, Starting S+1 If the patient does not have a history or suspected case of Heparin-Induced Thrombocytopenia (HIT) do NOT order this medication. Contraindicated in patients LESS than 50kg, prior to surgery/invasive procedure, or CrCl LESS than 30 mL/min This patient has a history of or suspected case of Heparin-Induced Thrombocytopenia (HIT):
()	heparin (porcine) injection	5,000 Units, subcutaneous, every 8 hours, S+1 at 6:00 AM
()	heparin (porcine) injection (Recommended for patients with high risk of bleeding, e.g. weight < 50kg and age > 75yrs)	5,000 Units, subcutaneous, every 12 hours, S+1 at 6:00 AM Recommended for patients with high risk of bleeding, e.g. weight LESS than 50kg and age GREATER than 75yrs.
()	rivaroxaban (XARELTO) tablet for hip or knee arthroplasty planned during this admission	10 mg, oral, daily at 0600 (time critical), Starting S+1 To be Given on Post Op Day 1.
()	warfarin (COUMADIN) tablet	Indications: oral, daily at 1700 (time critical), Starting S+1
()	Pharmacy consult to manage warfarin (COUMADIN)	Indication: STAT, Until discontinued, Starting S Indication:
[]	Mechanical Prophylaxis (Single Response)	
()	Contraindications exist for mechanical prophylaxis	Routine, Once No mechanical VTE prophylaxis due to the following contraindication(s):
()	Place/Maintain sequential compression device continuous	Routine, Continuous

() Place sequential compression device and antiembolic stockings	"And" Linked Panel
[] Place/Maintain sequential compression device continuous	Routine, Continuous
Place antiembolic stockings	Pouting Once
[] Prace antiembolic stockings	Routine, Once
Labs	
Labs Today - HMH	
CBC and differential	Once
Comprehensive metabolic panel	Once
[] Folate	Once
[] GM1 Ab panel	Once
[] Hemoglobin A1c	Once
[] HIV Ag/Ab combination	Once
[X] IgA	Once
Miscellaneous referral test	Once
	C Jejuni Antibodies
[] Oligoclonal banding	Once
Protein electrophoresis, serum	Once
Sedimentation rate, automated	Once
[] T3	Once
T4, free	Once
[] TSH	Once
Thyroxine binding globulin	Once
T uptake	Once
[] Vitamin B12	Once
Urinalysis screen and microscopy, with reflex to culture	Once Specimen Source: Urine
	Specimen Site:
Labs Today - HMSL/HMW	Specimen site.
Labs Today - HMSL/HMW [] CBC and differential	Once
	·
CBC and differential Comprehensive metabolic panel Folate	Once
CBC and differential Comprehensive metabolic panel	Once Once
[] CBC and differential [] Comprehensive metabolic panel [] Folate [] GM1 Ab panel [] Hemoglobin A1c	Once Once
CBC and differential Comprehensive metabolic panel Folate GM1 Ab panel	Once Once Once Once
[] CBC and differential [] Comprehensive metabolic panel [] Folate [] GM1 Ab panel [] Hemoglobin A1c [] Rapid HIV 1 & 2 [X] IgA	Once Once Once Once Once
[] CBC and differential [] Comprehensive metabolic panel [] Folate [] GM1 Ab panel [] Hemoglobin A1c [] Rapid HIV 1 & 2	Once Once Once Once Once Once Once Once
[] CBC and differential [] Comprehensive metabolic panel [] Folate [] GM1 Ab panel [] Hemoglobin A1c [] Rapid HIV 1 & 2 [X] IgA [] Miscellaneous referral test	Once Once Once Once Once Once Once Once
[] CBC and differential [] Comprehensive metabolic panel [] Folate [] GM1 Ab panel [] Hemoglobin A1c [] Rapid HIV 1 & 2 [X] IgA [] Miscellaneous referral test [] Oligoclonal banding	Once Once Once Once Once Once Once Once
[] CBC and differential [] Comprehensive metabolic panel [] Folate [] GM1 Ab panel [] Hemoglobin A1c [] Rapid HIV 1 & 2 [X] IgA [] Miscellaneous referral test [] Oligoclonal banding [] Protein electrophoresis, serum	Once Once Once Once Once Once Once Once
[] CBC and differential [] Comprehensive metabolic panel [] Folate [] GM1 Ab panel [] Hemoglobin A1c [] Rapid HIV 1 & 2 [X] IgA [] Miscellaneous referral test [] Oligoclonal banding [] Protein electrophoresis, serum [] Sedimentation rate, automated	Once Once Once Once Once Once Once Once
[] CBC and differential [] Comprehensive metabolic panel [] Folate [] GM1 Ab panel [] Hemoglobin A1c [] Rapid HIV 1 & 2 [X] IgA [] Miscellaneous referral test [] Oligoclonal banding [] Protein electrophoresis, serum [] Sedimentation rate, automated [] T3	Once Once Once Once Once Once Once Once
[] CBC and differential [] Comprehensive metabolic panel [] Folate [] GM1 Ab panel [] Hemoglobin A1c [] Rapid HIV 1 & 2 [X] IgA [] Miscellaneous referral test [] Oligoclonal banding [] Protein electrophoresis, serum [] Sedimentation rate, automated [] T3 [] T4, free	Once Once Once Once Once Once Once Once
[] CBC and differential [] Comprehensive metabolic panel [] Folate [] GM1 Ab panel [] Hemoglobin A1c [] Rapid HIV 1 & 2 [X] IgA [] Miscellaneous referral test [] Oligoclonal banding [] Protein electrophoresis, serum [] Sedimentation rate, automated [] T3 [] T4, free [] TSH	Once Once Once Once Once Once Once Once
[] CBC and differential [] Comprehensive metabolic panel [] Folate [] GM1 Ab panel [] Hemoglobin A1c [] Rapid HIV 1 & 2 [X] IgA [] Miscellaneous referral test [] Oligoclonal banding [] Protein electrophoresis, serum [] Sedimentation rate, automated [] T3 [] T4, free [] TSH [] Thyroxine binding globulin	Once Once Once Once Once Once Once Once
[] CBC and differential [] Comprehensive metabolic panel [] Folate [] GM1 Ab panel [] Hemoglobin A1c [] Rapid HIV 1 & 2 [X] IgA [] Miscellaneous referral test [] Oligoclonal banding [] Protein electrophoresis, serum [] Sedimentation rate, automated [] T3 [] T4, free [] TSH [] Thyroxine binding globulin [] T uptake	Once Once Once Once Once Once Once Once
[] CBC and differential [] Comprehensive metabolic panel [] Folate [] GM1 Ab panel [] Hemoglobin A1c [] Rapid HIV 1 & 2 [X] IgA [] Miscellaneous referral test [] Oligoclonal banding [] Protein electrophoresis, serum [] Sedimentation rate, automated [] T3 [] T4, free [] TSH [] Thyroxine binding globulin [] T uptake [] Vitamin B12	Once Once Once Once Once Once Once Once
[] CBC and differential [] Comprehensive metabolic panel [] Folate [] GM1 Ab panel [] Hemoglobin A1c [] Rapid HIV 1 & 2 [X] IgA [] Miscellaneous referral test [] Oligoclonal banding [] Protein electrophoresis, serum [] Sedimentation rate, automated [] T3 [] T4, free [] TSH [] Thyroxine binding globulin [] T uptake	Once Once Once Once Once Once Once Once
[] CBC and differential [] Comprehensive metabolic panel [] Folate [] GM1 Ab panel [] Hemoglobin A1c [] Rapid HIV 1 & 2 [X] IgA [] Miscellaneous referral test [] Oligoclonal banding [] Protein electrophoresis, serum [] Sedimentation rate, automated [] T3 [] T4, free [] TSH [] Thyroxine binding globulin [] T uptake [] Vitamin B12	Once Once Once Once Once Once Once Once
[] CBC and differential [] Comprehensive metabolic panel [] Folate [] GM1 Ab panel [] Hemoglobin A1c [] Rapid HIV 1 & 2 [X] IgA [] Miscellaneous referral test [] Oligoclonal banding [] Protein electrophoresis, serum [] Sedimentation rate, automated [] T3 [] T4, free [] TSH [] Thyroxine binding globulin [] T uptake [] Vitamin B12 [] Urinalysis screen and microscopy, with reflex to culture	Once Once Once Once Once Once Once Once
[] CBC and differential [] Comprehensive metabolic panel [] Folate [] GM1 Ab panel [] Hemoglobin A1c [] Rapid HIV 1 & 2 [X] IgA [] Miscellaneous referral test [] Oligoclonal banding [] Protein electrophoresis, serum [] Sedimentation rate, automated [] T3 [] T4, free [] TSH [] Thyroxine binding globulin [] T uptake [] Vitamin B12 [] Urinalysis screen and microscopy, with reflex to culture	Once Once Once Once Once Once Once Once
[] CBC and differential [] Comprehensive metabolic panel [] Folate [] GM1 Ab panel [] Hemoglobin A1c [] Rapid HIV 1 & 2 [X] IgA [] Miscellaneous referral test [] Oligoclonal banding [] Protein electrophoresis, serum [] Sedimentation rate, automated [] T3 [] T4, free [] TSH [] Thyroxine binding globulin [] T uptake [] Vitamin B12 [] Urinalysis screen and microscopy, with reflex to culture Labs Today - HMSTJ, HMTW, HMSJ, HMWB [] CBC and differential	Once Once Once Once Once Once Once Once

[] Hemoglobin A1c	Once
[] HIV 1, 2 antibody	Once
[X] IgA	Once
[] Miscellaneous referral test	Once
	C Jejuni Antibodies
[] Oligoclonal banding	Once
[] Protein electrophoresis, serum	Once
[] Sedimentation rate, automated	Once
[] T3	Once
[] T4, free	Once
[] TSH	Once
[] Thyroxine binding globulin	Once
[] T uptake	Once
[] Vitamin B12	Once
[] Urinalysis screen and microscopy, with reflex to culture	Once Specimen Source: Urine Specimen Site:
Cardiology	
Cardiology	
[] Electrocardiogram, 12-lead	Routine, Once For 1 Occurrences
	Clinical Indications:
	Interpreting Physician:
[] Echocardiogram complete w contrast and 3D if needed	Routine, 1 time imaging
Imaging	
Diagnostic MRI/MRA	
[] MRI Brain W Contrast	Routine, 1 time imaging For 1
[] MRI Brain Wo Contrast	Routine, 1 time imaging For 1
[] MRI Brain W Wo Contrast	Routine, 1 time imaging For 1
[] MRI Cervical Spine Wo Contrast	Routine, 1 time imaging For 1
[] MRI Cervical Spine W Wo Contrast	Routine, 1 time imaging For 1
[] MRI Thoracic Spine Wo Contrast	Routine, 1 time imaging For 1
MRI Thoracic Spine W Wo Contrast	Routine, 1 time imaging For 1
MRI Lumbar Spine Wo Contrast	Routine, 1 time imaging For 1
[] MRI Lumbar Spine W Wo Contrast	Routine, 1 time imaging For 1
Diagnostic X-Ray	
[] Chest 1 Vw Portable	Routine, 1 time imaging For 1
[] Chest 2 Vw	Routine, 1 time imaging For 1
Other Diagnostic Studies	
Other Diagnostic Studies	
[] Lumbar Puncture by Radiology	
[] Lumbar Puncture	Routine, 1 time imaging For 1
	If tap is traumatic, send first and last tube for cell count., Imaging Procedure
[] CSF cell count with differential	Once, Cerebrospinal fluid
	Specimen to be drawn in Interventional Radiology area.,
	Imaging Proc. Labs
[] CSF protein	Once, Cerebrospinal fluid
[] [] CO. Protoni	Specimen to be drawn in Interventional Radiology area.,
	Imaging Proc. Labs
[] Glucose, CSF	Once, Cerebrospinal fluid
	Specimen to be drawn in Interventional Radiology area.,
	Imaging Proc. Labs

[] CSF culture	Once, Cerebrospinal fluid
	Includes a Gram stain. Specimen to be drawn in Interventional Radiology area., Imaging Proc. Labs
[] Fungus culture	Once, Cerebrospinal fluid
	Specimen to be drawn in Interventional Radiology area., Imaging Proc. Labs
[] AFB culture	Once, Cerebrospinal fluid
	Specimen to be drawn in Interventional Radiology area., Imaging Proc. Labs
[] Cryptococcal antigen	Once, Cerebrospinal fluid
	Specimen to be drawn in Interventional Radiology area., Imaging Proc. Labs
[] Cytology (non-gynecological) request	A paper requisition will print when this order is submitted. The printout must accompany the specimen to the lab.
[] LDH, CSF	Once, Cerebrospinal fluid
	Specimen to be drawn in Interventional Radiology area, Imaging Proc. Labs
[] Immuno G synthesis rate, CSF	Once
	This panel requires serum and CSF samples to be sent at the same time. The panel cannot be ordered again within 72
	hours.
	Specimen to be drawn in Interventional Radiology area., Imaging Proc. Labs
D-dimer, quantitative	Once
[], quantum	Specimen to be drawn in Interventional Radiology area., Imaging Proc. Labs
[] Gabapentin level	Once
	Specimen to be drawn in Interventional Radiology area., Imaging Proc. Labs
[] CSF VDRL	Once, Cerebrospinal fluid
	Specimen to be drawn in Interventional Radiology area., Imaging Proc. Labs
[] Lyme disease reflexive panel, CSF	Once, Cerebrospinal fluid
	Specimen to be drawn in Interventional Radiology area., Imaging Proc. Labs
[] Flow cytometry evaluation	Once
	Panel:
	Specimen Type: Reason for evaluation:
	Specimen to be drawn in Interventional Radiology area.,
	Imaging Proc. Labs
[] Myelin basic protein, CSF	Once, Cerebrospinal fluid
	Specimen to be drawn in Interventional Radiology area., Imaging Proc. Labs
[] BK virus by PCR	Once
[] Bit viids by i Git	Specimen Source: Cerebrospinal Fluid
	Specimen to be drawn in Interventional Radiology area.,
	Imaging Proc. Labs
[] Cytomegalovirus (CMV), PCR	Once
	Specimen Source: Cerebrospinal Fluid Specimen to be drawn in Interventional Radiology area.,
	Imaging Proc. Labs
[] Epstein Barr Virus (EBV) by PCR	Once
. , ,	Specimen Source: Cerebrospinal Fluid
	Specimen to be drawn in Interventional Radiology area., Imaging Proc. Labs
[] Enterovirus by PCR	Once
, -	Specimen Source:
	Specimen to be drawn in Interventional Radiology area.,
	Imaging Proc. Labs

[] Herpes simplex virus, PCR	Once Specimen Source: Cerebrospinal Fluid
	Specimen to be drawn in Interventional Radiology area., Imaging Proc. Labs
[] JC virus, quantitative PCR	Once
	Specimen Source:
	Specimen to be drawn in Interventional Radiology area., Imaging Proc. Labs
[] Toxoplasma gondii qPCR - Viracor	Once
	Specimen to be drawn in Interventional Radiology area., Imaging Proc. Labs
[] Varicella zoster, PCR	Once
	Specimen Source: Cerebrospinal Fluid
	Specimen to be drawn in Interventional Radiology area., Imaging Proc. Labs
[] West Nile virus by PCR, CSF	Once, Cerebrospinal fluid
, ,	Specimen to be drawn in Interventional Radiology area.,
[] Olimpland handing CCF	Imaging Proc. Labs
[] Oligoclonal banding, CSF	Once Specimen to be drawn in Interventional Radiology area.,
<u> </u>	Imaging Proc. Labs
[] West Nile virus antibody panel, CSF	Once, Cerebrospinal fluid
	Specimen to be drawn in Interventional Radiology area., Imaging Proc. Labs
[] Angiotensin converting enzyme, CSF	Once, Cerebrospinal fluid
	Specimen to be drawn in Interventional Radiology area.,
	Imaging Proc. Labs
Respiratory	
Respiratory	Deutine Continueus
[] Oxygen therapy - Nasal cannula	Routine, Continuous Device 1: Nasal Cannula
	Device 1: Nasal Cannula Rate in liters per minute: 2 lpm
	Device 1: Nasal Cannula Rate in liters per minute: 2 lpm Rate in tenths of a liter per minute:
	Device 1: Nasal Cannula Rate in liters per minute: 2 lpm Rate in tenths of a liter per minute: O2 %:
	Device 1: Nasal Cannula Rate in liters per minute: 2 lpm Rate in tenths of a liter per minute:
	Device 1: Nasal Cannula Rate in liters per minute: 2 lpm Rate in tenths of a liter per minute: O2 %: Titrate to keep O2 Sat Above: 92% Indications for O2 therapy: Device 2:
[] Oxygen therapy - Nasal cannula	Device 1: Nasal Cannula Rate in liters per minute: 2 lpm Rate in tenths of a liter per minute: O2 %: Titrate to keep O2 Sat Above: 92% Indications for O2 therapy: Device 2: Device 3:
	Device 1: Nasal Cannula Rate in liters per minute: 2 lpm Rate in tenths of a liter per minute: O2 %: Titrate to keep O2 Sat Above: 92% Indications for O2 therapy: Device 2:
Oxygen therapy - Nasal cannula Vital capacity only	Device 1: Nasal Cannula Rate in liters per minute: 2 lpm Rate in tenths of a liter per minute: O2 %: Titrate to keep O2 Sat Above: 92% Indications for O2 therapy: Device 2: Device 3: Routine, Once Forced Vital Capacity. Record in chart. If poor oral seal please use face mask.
[] Oxygen therapy - Nasal cannula	Device 1: Nasal Cannula Rate in liters per minute: 2 lpm Rate in tenths of a liter per minute: O2 %: Titrate to keep O2 Sat Above: 92% Indications for O2 therapy: Device 2: Device 3: Routine, Once Forced Vital Capacity. Record in chart. If poor oral seal please use face mask. Routine, Once
Oxygen therapy - Nasal cannula Vital capacity only	Device 1: Nasal Cannula Rate in liters per minute: 2 lpm Rate in tenths of a liter per minute: O2 %: Titrate to keep O2 Sat Above: 92% Indications for O2 therapy: Device 2: Device 3: Routine, Once Forced Vital Capacity. Record in chart. If poor oral seal please use face mask.
Oxygen therapy - Nasal cannula Vital capacity only	Device 1: Nasal Cannula Rate in liters per minute: 2 lpm Rate in tenths of a liter per minute: O2 %: Titrate to keep O2 Sat Above: 92% Indications for O2 therapy: Device 2: Device 3: Routine, Once Forced Vital Capacity. Record in chart. If poor oral seal please use face mask. Routine, Once
Oxygen therapy - Nasal cannula	Device 1: Nasal Cannula Rate in liters per minute: 2 lpm Rate in tenths of a liter per minute: O2 %: Titrate to keep O2 Sat Above: 92% Indications for O2 therapy: Device 2: Device 3: Routine, Once Forced Vital Capacity. Record in chart. If poor oral seal please use face mask. Routine, Once
[] Oxygen therapy - Nasal cannula [] Vital capacity only [] Negative inspiratory force Rehab	Device 1: Nasal Cannula Rate in liters per minute: 2 lpm Rate in tenths of a liter per minute: O2 %: Titrate to keep O2 Sat Above: 92% Indications for O2 therapy: Device 2: Device 3: Routine, Once Forced Vital Capacity. Record in chart. If poor oral seal please use face mask. Routine, Once
[] Oxygen therapy - Nasal cannula [] Vital capacity only [] Negative inspiratory force Rehab Consults Ancillary Consults	Device 1: Nasal Cannula Rate in liters per minute: 2 lpm Rate in tenths of a liter per minute: O2 %: Titrate to keep O2 Sat Above: 92% Indications for O2 therapy: Device 2: Device 3: Routine, Once Forced Vital Capacity. Record in chart. If poor oral seal please use face mask. Routine, Once
[] Oxygen therapy - Nasal cannula [] Vital capacity only [] Negative inspiratory force Rehab Consults	Device 1: Nasal Cannula Rate in liters per minute: 2 lpm Rate in tenths of a liter per minute: O2 %: Titrate to keep O2 Sat Above: 92% Indications for O2 therapy: Device 2: Device 3: Routine, Once Forced Vital Capacity. Record in chart. If poor oral seal please use face mask. Routine, Once Record in chart.
[] Oxygen therapy - Nasal cannula [] Vital capacity only [] Negative inspiratory force Rehab Consults Ancillary Consults [] Consult to Case Management	Device 1: Nasal Cannula Rate in liters per minute: 2 lpm Rate in tenths of a liter per minute: O2 %: Titrate to keep O2 Sat Above: 92% Indications for O2 therapy: Device 2: Device 3: Routine, Once Forced Vital Capacity. Record in chart. If poor oral seal please use face mask. Routine, Once Record in chart.
[] Oxygen therapy - Nasal cannula [] Vital capacity only [] Negative inspiratory force Rehab Consults Ancillary Consults [] Consult to Case Management [] Consult to Social Work	Device 1: Nasal Cannula Rate in liters per minute: 2 lpm Rate in tenths of a liter per minute: O2 %: Titrate to keep O2 Sat Above: 92% Indications for O2 therapy: Device 2: Device 3: Routine, Once Forced Vital Capacity. Record in chart. If poor oral seal please use face mask. Routine, Once Record in chart. Consult Reason: Reason for Consult: Special Instructions:
[] Oxygen therapy - Nasal cannula [] Vital capacity only [] Negative inspiratory force Rehab Consults Ancillary Consults [] Consult to Case Management [] Consult to Social Work [] PT eval and treat	Device 1: Nasal Cannula Rate in liters per minute: 2 lpm Rate in tenths of a liter per minute: O2 %: Titrate to keep O2 Sat Above: 92% Indications for O2 therapy: Device 2: Device 3: Routine, Once Forced Vital Capacity. Record in chart. If poor oral seal please use face mask. Routine, Once Record in chart. Consult Reason: Reason for Consult: Special Instructions: Weight Bearing Status: Special Instructions: Location of Wound? Special Instructions:
[] Oxygen therapy - Nasal cannula [] Vital capacity only [] Negative inspiratory force Rehab Consults Ancillary Consults [] Consult to Case Management [] Consult to Social Work [] PT eval and treat [] Consult PT wound care	Device 1: Nasal Cannula Rate in liters per minute: 2 lpm Rate in tenths of a liter per minute: O2 %: Titrate to keep O2 Sat Above: 92% Indications for O2 therapy: Device 2: Device 3: Routine, Once Forced Vital Capacity. Record in chart. If poor oral seal please use face mask. Routine, Once Record in chart. Consult Reason: Reason for Consult: Special Instructions: Weight Bearing Status: Special Instructions: Location of Wound?
[] Oxygen therapy - Nasal cannula [] Vital capacity only [] Negative inspiratory force Rehab Consults Ancillary Consults [] Consult to Case Management [] Consult to Social Work [] PT eval and treat [] Consult PT wound care [] OT eval and treat	Device 1: Nasal Cannula Rate in liters per minute: 2 lpm Rate in tenths of a liter per minute: O2 %: Titrate to keep O2 Sat Above: 92% Indications for O2 therapy: Device 2: Device 3: Routine, Once Forced Vital Capacity. Record in chart. If poor oral seal please use face mask. Routine, Once Record in chart. Consult Reason: Reason for Consult: Special Instructions: Weight Bearing Status: Special Instructions: Location of Wound? Special Instructions: Weight Bearing Status: Weight Bearing Status:

Speech Language Pathology	Reason for SLP? Bedside Swallow exam	
Consult to wound ostomy care nurse	Reason for consult:	
[] Consult to mount octomy sure name	Reason for consult:	
	Reason for consult:	
	Reason for consult:	
	Consult for NPWT:	
	Reason for consult:	
Consult to Respiratory Therapy	Reason for Consult? Evaluate and treat	